Ocugen FY2024 net loss $0.20; advances three gene therapy programs toward BLA filings

Ocugen, Inc.

Q4 net loss $0.05/share; full-year net loss $0.20/share vs $0.26 in 2023.
Cash $58.8M as of Dec 31, 2024; runway into Q1 2026; $65M financing secured in H2 2024.
OCU400 Phase 3 RP enrollment on track for H1 2025; BLA/MAA target mid-2026.
OCU410ST Stargardt Phase 2/3 pivotal trial FDA-aligned; BLA target 2027.
OCU410 GA completed Phase 2 dosing; no serious adverse events; BLA target 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.